Market Research Report
Global Trans Catheter Aortic Valve Replacement Market - 2019-2026
|Published by||DataM Intelligence||Product code||803282|
|Published||Content info||130-180 Pages
Delivery time: 1-2 business days
|Global Trans Catheter Aortic Valve Replacement Market - 2019-2026|
|Published: February 1, 2019||Content info: 130-180 Pages||
Trans catheter aortic valve replacement is a viable, less invasive and increasingly common alternative for the patients prone to high surgical risk in surgical aortic replacement and majorly in geriatrics population. In these procedures, a new aortic valve is replaced without replacing the previous, damaged valve with the help of a specialized catheter with the process similar to stenting. These procedures include clinical examination, echocardiogram, CT scan, and catheterization. Such process of treatment is fairly new, and USFDA has approved for people with aortic stionis who are considered an intermediate or high-risk patient for standard valve replacement surgery.
The global trans catheter aortic valve replacement market was worth $XX billion in 2018 and is forecasted to reach $XX billion by 2026, at a CAGR of XX% during the forecast period.
Increase in cardiovascular diseases, aortic stenosis prevalence, global hospital admission related to aortic stenosis, increase in shift towards minimally invasive surgeries across the globe and increase in geriatric population are driving the Trans catheter aortic valve replacement market and expected to remain high during the forecast period.
According to the American Heart Association in 2018, estimated that the annual new cases of heart attack in United States is 580,000 and 210,00 reoccurent attacks. The averge age of fisrt heartattack is 65.3 years in males and 71.8 years in females.
According to the researchers in Mayo Clinics a non-profit organisation in 2018 stated that between 2003-2014 the aortic related admissions increased from 16 to 35.5 cases per 100,000 admissions in the United States.
Major factors hindering the global trans catheter aortic valve replacement market are high risk associated with the surgery assisted with trans catheter valve which cause damage to the heart around the valve and there can be a leakage around the artificial valve.
Global trans catheter aortic valve replacement market is segmented on medical procedure which includes tranfemoral implantation, trans aortic implantation, and transapial implantation. In transfemoral implantation the delivery sheath is inserted through the femoral artery and in case of transapical the sheath is inserted through the apex of the heart. The transaortic implantation the delivery sheath is inserted into the aorta through the small incision create on the top of the sternum. Transfemoral procedure segment dominates the global trans catheter aortic valve replacement market due to an increase in extensive clinical studies to develop these procedures and also an extensive usage these products is expected to remain high during the forecast period.
On January 2019, JC Medical has a successful treatment of first U.S. patient with the companies transfemoral trans catheter valve aortic valve replacement device the J-valve TF system at the Christ Hospital.
The global trans catheter aortic valve replacement Market is segmented into North America, Europe, Asia Pacific, South America, and Middle East and Africa.
North America dominates the global trans catheter aortic valve replacement market due to increase in adoption of TCAVR technology in hospitals and ambulatory surgical centers, open heart surgeries and increases in surgical procedures using trans catheter aortic valve replacement, is expected to remain high during the forecast period.
Between 2012-2016 Cleveland clinics, USA Trans catheter aortic valve replacement team performed more than 1200 procedures, which is further expected to grow 1.2x times more over the forecast period.
According to Sklar Corp, a leading provider of the high-quality surgical instrument in March 2017, heart diseases are the leading cause of deaths in both men and women, about half million coronary bypass surgeries are performed each year in U.S.
USFDA approvals, new product launches, and initiation of clinical trails of pipeline produts in sposnsorship with different players in medical indstry in trans catheter aortic valve replacement products are driving the global trans catheter aortic valve replacement market.
In January 2019, Thubrikar Aortic Valve Inc. launched the first human implant of the optimum trans aortic valve using their Trans catheter aortic valve implantation system and commenced the clinical trails on sponsorship by Brazillian License, Labcor Laboratorios Ltda.
In December 2018, Edwards Lifesciences Corp received USFDA approval for Sapien 3 ultra system.
Major market players in trans catheter aortic valve replacement are: Boston Scientific Corp, Edwards Lifesciences Corporation, St. Jude Medical Inc., Abbott, HLT Medical, Thubrikar Aortic Valve Inc and JC Medical.